Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lebrikizumab in chronic rhinosinusitis with nasal polyps on background intranasal corticosteroids
CTR20241693Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lebrikizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Eli Lilly and Company. Started Oct 2024; status: active.
02
Drugs
lebrikizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20241693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241693.